Children with First Relapsed T-cell Acute Lymphoblastic Leukemia
Conditions
Interventions
experimental group:Dasatinib in combination with intensive induction therapy
Sponsors
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Eligibility
Sex/Gender
All
Age
1 Years to 21 Years
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with first recurrence of T-ALL. The first bone marrow relapse (with or without extramedullary infiltration) of T-ALL was necessary; 2. Patients aged 1-21 years; 3. Patients who comply with the relevant guidelines of the institutional review committee, NCI, FDA and OHRP, and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Research participants or legal guardians are unable or unwilling to provide written informed consent; 3. Patients who use chemotherapy drugs other than those specified in the program; 4. Non-t-all patients; 5. Patients with etp-all; 6. Patients with abnormal liver function (direct bilirubin 3 times higher than normal upper limit); 7. Patients with abnormal renal function (EGFR = 2; 11. Patients with varicella, mumps, influenza, cytomegalovirus, active EB virus and other infectious diseases; 12. Patients with previous grade 3-4 pancreatitis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dasatinib window therapy;Mid-Induction MRD response;End-of-Induction MRD response;End of Consolidation-MRD response; | — |
Countries
China
Contacts
Public ContactZhu Xiaofan
Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Outcome results
None listed